Are there any notable changes in the capital structure, such as new debt, equity offerings, or share buybacks?

Based on the excerpt you provided – the headline, a brief introductory paragraph, and the metadata (date, ticker, source, and category) – there is no specific information about changes to Whitehawk Therapeutics’ capital structure. The text stops after announcing that the company “today announced financial results for the second…,” and it does not include any of the typical sections where a company would disclose:

What this means for your question

• No notable capital‑structure events are evident in the snippet you shared.
  
• It is possible that the full earnings release (which likely contains the “Management’s Discussion and Analysis” and “Liquidity and Capital Resources” sections) may discuss debt repayments, new financing, equity issuances, or share‑repurchase activity. However, without those sections we cannot confirm any such changes.

Recommendation

• If you need a definitive answer, locate the complete press release (usually available on Whitehawk Therapeutics’ investor‑relations website or the full PR Newswire article). Look for the sections titled “Liquidity and Capital Resources,” “Financing,” or any footnotes to the financial statements, where companies typically disclose:
  • New debt facilities or term‑loan agreements
  • Stock issuances, convertible notes, or warrants
  • Share‑repurchase authorizations or transactions completed during the quarter
• Once you have that detailed information, you can verify whether any of those items occurred in Q2 2025.

In summary: The limited information provided does not reveal any new debt, equity offerings, or share‑buybacks for Whitehawk Therapeutics in the second quarter of 2025. To be certain, a review of the full earnings release is required.